Perrigo Company plc Deferred Tax Liabilities, Property, Plant and Equipment
Perrigo Company plc (PRGO) had Deferred Tax Liabilities, Property, Plant and Equipment of $340.70 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment · last filed 2026-02-26
- 2025-12-31: Deferred Tax Liabilities, Property, Plant and Equipment $340.70M.
- 2024-12-31: Deferred Tax Liabilities, Property, Plant and Equipment $428.80M; Deferred Tax Liabilities, Property, Plant and Equipment as first filed $382.50M.
- 2023-12-31: Deferred Tax Liabilities, Property, Plant and Equipment $475.90M.
- 2022-12-31: Deferred Tax Liabilities, Property, Plant and Equipment $511.50M.
| Period end | Deferred Tax Liabilities, Property, Plant and Equipment | Deferred Tax Liabilities, Property, Plant and Equipment as first filed |
|---|---|---|
| 2025-12-31 | $340.70M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $428.80M 10-K · filed 2026-02-26 | $382.50M 10-K · filed 2025-02-28 |
| 2023-12-31 | $475.90M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $511.50M 10-K · filed 2024-02-27 | |
| 2021-12-31 | $320.50M 10-K · filed 2023-02-28 | |
| 2020-12-31 | $393.70M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $366.70M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $371.20M 10-K · filed 2020-02-27 | |
| 2017-12-31 | $457.80M 10-K · filed 2019-02-27 | |
| 2016-12-31 | $765.20M 10-K · filed 2018-03-01 | |
| 2015-12-31 | $1.55B 10-K · filed 2018-03-01 | $1.81B 10-KT · filed 2016-02-25 |
| 2015-06-27 | $1.62B 10-K · filed 2017-05-22 | $1.89B 10-K · filed 2015-08-13 |
| 2014-06-28 | $982.60M 10-KT · filed 2016-02-25 | |
| 2013-06-29 | $203.30M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |